Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Progenics Pharmaceuticals (NasdaqNM:PGNX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug  6Earnings Announcement
Location
777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: (914) 789-2800
Fax: (914) 789-2817
Email: info@progenics.com
Employees (last reported count): 54
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 65%
·Institutional: 48% (138% of float)
(79 institutions)
·Net Inst. Buying: 44.0K shares (+0.74%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for the treatment and prevention of viral, cancer and other life-threatening diseases. The Company applies its immunology expertise to develop biopharmaceuticals to fight viral diseases, such as HIV (human immunodeficiency virus) infection, and cancers, such as malignant melanoma and prostate cancer. Based on its participation in the discoveries of two major receptors for HIV, the Company is engaged in the research and development of therapeutic products designed to block entry of HIV into human immune system cells. The Company is also engaged in programs to discover and develop novel small-molecule HIV therapeutics that target the fusion co-receptors of the virus and other programs focusing on HIV attachment and fusion.
More from Market Guide: Expanded Business Description

Financial Summary
Progenics Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of innovative products for the treatment and prevention of cancer, viral and other life-threatening diseases. For the six months ended 6/30/01, total revenues rose 8% to $7.3 million. Net income totaled $5.7 million vs. a loss of $2.9 million. Results reflect revenues from the collaborations with Bristol-Myers and Hoffman-La Roche and a $9.9 million termination payment.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Paul Maddon, M.D., Ph.D., 41
Chairman, CEO, Chief Science Officer
$552K$132K
Ronald Prentki, 43
Pres
351K1.3M
Robert McKinney, 44
VP of Fin. and Operations and Treasurer
184K2.0M
Richard Krawiec, Ph.D., 53
VP of Investor Relations and Corp. Communications
--  --  
Robert Israel, M.D., 44
VP of Medical Affairs
291K1.9M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PGNXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 28-Mar-2001
$10.00 
Recent Price$17.94 
52-Week High
on 3-Nov-2000
$34.00 
Beta2.22 
Daily Volume (3-month avg)39.6K
Daily Volume (10-day avg)17.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-40.2%
52-Week Change
relative to S&P500
-19.8%
Share-Related Items
Market Capitalization$222.3M
Shares Outstanding12.4M
Float4.30M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$5.76 
Earnings (ttm)$0.16 
Earnings (mrq)$0.38 
Sales (ttm)$1.11 
Cash (mrq)$4.36 
Valuation Ratios
Price/Book (mrq)3.11 
Price/Earnings (ttm)110.74 
Price/Sales (ttm)16.15 
Income Statements
Sales (ttm)$14.5M
EBITDA (ttm)-$6.43M
Income available to common (ttm)$2.66M
Profitability
Profit Margin (ttm)18.4%
Operating Margin (ttm)-49.7%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)3.85%
Return on Equity (ttm)3.97%
Financial Strength
Current Ratio (mrq)24.99 
Debt/Equity (mrq)0 
Total Cash (mrq)$54.0M
Short Interest
As of 8-Aug-2001
Shares Short206.0K
Percent of Float4.8%
Shares Short
(Prior Month)
247.0K
Short Ratio12.88 
Daily Volume16.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.